Current studies on the treatment of tumors by GM-SCF or IL-21 mostly focus on enhancing CTL and NK cell-mediated activity [20,21] or increasing genes that can be expressed by tumors and recognized by NK and CTL cells in tumor tissues [22]. The gene discussed is KITLG; the disease is neoplasm.